One Asset, Two Rare Pediatric Disease Designations: Quoin’s Regulatory Build

Quoin Pharmaceuticals (NASDAQ: QNRX) announced on September 8 that the FDA granted Rare Pediatric Disease Designation to QRX003 for the treatment of Peeling Skin Syndrome. It is the second RPD designation the agency has granted for QRX003, following the designation previously granted in Netherton Syndrome. Peeling Skin Syndrome is a rare genetic disease that presents at birth or in infancy and causes continuous shedding of the outer layers of the skin, along with severe pain and chronic itch. There is no approved treatment.

QRX003 is an investigational topical serine protease inhibitor lotion. In Netherton Syndrome, it is being evaluated in multiple whole-body clinical trials. Quoin reported interim results on August 28 from CL-QRX003-004, a Phase 2/3 study, where four of the first six participants to complete 12 weeks of treatment met the primary endpoint with statistical significance. Recruitment of all 20 participants is expected to complete by the end of 2026, with topline data in the second quarter of 2027 and a potential NDA filing in 2027. In Peeling Skin Syndrome, the IND has been cleared and Quoin expects to initiate a Phase 2 study in the second half of 2026, enrolling up to 12 pediatric and adult patients across the U.S. and Europe.

Two designations for one asset across two separate indications are worth pausing on. QRX003 is now no longer simply a Netherton Syndrome program with additional indications merely on a development list. Quoin is running two programs off one product, at two different stages of development, on separate regulatory tracks.

Designations in the U.S., Europe and Japan

In Netherton Syndrome, QRX003 has been granted Orphan Drug Designation, Rare Pediatric Disease Designation and Fast Track Designation by the FDA, and Orphan Drug Designation in the European Union and Japan. Quoin has also filed for Breakthrough Medicine Designation with the Saudi Food and Drug Authority.

Together, these designations can provide development incentives, review advantages and, in some cases, potential market exclusivity. What the accumulation indicates is sustained regulatory engagement across the three territories Quoin has identified as core commercial markets.. The PSS designation extends that engagement to a second rare disease.

What a Priority Review Voucher is worth

Rare Pediatric Disease Designation carries a distinct feature. Upon approval of a qualifying application, the sponsor may receive a Priority Review Voucher, which can be redeemed for priority review of another application or sold and transferred to a third party. Vouchers have traded on the open market for substantial sums, and the proceeds are non-dilutive.  For a company of Quoin’s size, the possibility of a non-dilutive funding path that runs through regulatory execution rather than the equity market is a meaningfully different value proposition than a follow-on offering.

A second platform on a different mechanism

QRX003 is one of two platforms. QRX009, Quoin’s proprietary topical rapamycin program, is being developed in lotion and dermal patch formulations across a separate group of rare diseases, including Pachyonychia Congenita, Gorlin Syndrome and Tuberous Sclerosis Complex. Investigator-led studies are planned in parallel, including a Pachyonychia Congenita study led by Professor Edel O’Toole at Queen Mary University of London.

The two platforms operate through different mechanisms and address different rare disease indications with limited or no approved treatments, and neither depends on the other clinically. Each carries its own development timeline and commercial potential.

QRX003 currently remains investigational in every indication Quoin is pursuing. What this new designation adds is a second FDA-recognized rare pediatric disease pathway for the same asset, with a separate clinical program.

For Quoin, the significance is less about one more designation than the structure taking shape around QRX003: one asset, multiple rare disease programs, and increasingly distinct regulatory paths advancing in parallel. In short QRX003 is becoming a pipeline in a single product.